Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes.

ABSTRACT:

Objective

The 23-valent pneumococcal polysaccharide vaccine is routinely recommended for adults with diabetes, but little is known about adherence to this recommendation and how vaccination of these adults affects costs related to pneumococcal disease.

Research design and methods

We used data from a commercial insurance claims dataset to examine a cohort of non-elderly adults with a new diagnosis of diabetes and adults with no diagnosis of diabetes from 2005 to 2014. We examined rates of pneumococcal polysaccharide vaccination and the relationship between vaccination and pneumococcal disease costs, comparing results for persons with a diagnosis of diabetes and those with no diagnosis of diabetes.

Results

Overall rates of pneumococcal polysaccharide vaccination among a

SUBMITTER: Hutton DW 

PROVIDER: S-EPMC9018094 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature